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Master’s Paper Abstract 
Title: An analysis the uptake of collaborative TB/HIV activities at fourteen TB clinics in 
Kinshasa, DRC. 
Objectives: We assessed the uptake of HIV activities when integrated into routine care at 14 TB 
clinics in Kinshasa, DRC. 
Design: Descriptive analysis of prospective data on patients registered with TB between 
February 2006 and December 2006. Data was collected using modified TB treatment cards to 
capture both TB and HIV activities. 
Results: Among 3521 patients with TB, a high uptake rate of HIV testing was achieved (mean 
90.2%), with large variation between clinics (range 65-99%). Almost all patients tested received 
post-test counseling (mean 95.8%, range 78-99%). The mean HIV prevalence rate was 16.7%, 
varying by clinic from 8.8 to 33.3%. Cotrimoxazole was initiated in most HIV co-infected 
patients (81.5%, range 63-91.5%). Referral of HIV-positive patients for psychosocial support 
increased over time from 32% in the 1st month of operation to 67% in the 10
th
 month, again 
varying widely by clinic (0 to 85%). Antiretroviral therapy (ART) initiation was sporadic and 
varied by month and clinic with a mean of 6.9% of patients receiving ART. Among the 39 
patients receiving ART, 28 (72%) started ART before TB diagnosis. Only 9 patients gained 
access to ART following HIV testing at the TB clinic. 
Discussion: High uptake of collaborative TB/HIV activities (HIV testing, posttest counseling 
and cotrimoxazole) was achieved when these activities were integrated into routine TB care.  
Access to ART was low among newly diagnosed co-infected patients. Quarterly monitoring and 
evaluation of performance of activities at the clinic level using visual charts of activities 
demonstrated variable performance between clinics over time.   
 1 
I. Introduction 
Tuberculosis (TB) remains one of the leading causes of infectious disease death 
worldwide causing 1.6 million deaths in 2005.
1 
  Twelve of the 15 countries with the highest 
rates of TB are found in Africa, and 28 percent of TB patients in Africa are estimated to be 
infected with HIV.  Eighty percent of the world’s TB/HIV co-infected patients reside in Africa.  
The Democratic Republic of the Congo (DRC) is identified as one of the 22 high burden of 
tuberculosis disease countries in the world with 356 new infections per 100,000 people and 73 
deaths per 100,000 people in 2005. While not as affected by HIV as parts of southern Africa, 17 
percent of TB patients in the DRC are estimated to be HIV positive and the DRC contains 4 
percent of the world’s TB/HIV cases.1  
Since the 1980’s, TB and HIV have developed a symbiotic relationship.  Many patients 
become latently infected with TB before contracting HIV.  As these patients become immune 
compromised, their systems can no longer contain latent TB infections and, as a result, they 
progress to active TB.  In Africa, TB is often the first sign of HIV infection and is the leading 
cause of death among HIV-infected patients.
2 
  A study in the early stages of the TB/HIV co-
epidemic in the DRC found that 41 percent of autopsies showed TB as the cause of death in 
HIV-patients in Kinshasa.
3 
   
In 2004, WHO recommended the implementation of collaborative TB/HIV activities.  In 
the DRC, tuberculosis clinics are not linked to HIV voluntary counseling and testing centers.  
Because there was little collaboration between the central TB and HIV efforts in the DRC, a 
group of UNC researchers provided technical assistance to the National TB and HIV programs to 
assess the feasibility of collaborative TB/HIV activities.  Through their research, they found that 
incorporating HIV testing activities into routine TB care was the most accepted and successful 
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way to offer HIV prevention and care to TB patients in the setting specific to Kinshasa.  These 
findings led to new national TB/HIV policy guidelines. 
This paper examines the rollout of collaborative TB/HIV activities for TB patients to 
fourteen clinics in Kinshasa, DRC.  We will describe the uptake of collaborative TB/HIV 
activities both overall and by individual clinics and discuss the process of monitoring and 
evaluating TB programs.  Ultimately, monitoring and evaluation will help to identify clinics that 
are in need of improvement that can be addressed through clinic interactions and quality 
improvement activities.   
 
II. Literature review 
 
A. Historical Context 
 
Because of the rapid emergence of the HIV epidemic in resource poor countries where 
tuberculosis is also present, the health care systems of many countries were not equipped to 
address patients with TB/HIV co-infections.  Tuberculosis control programs are historically 
vertical programs that take a public health approach to case-finding and treatment of active, 
smear-positive, pulmonary tuberculosis.  Largely because of the stigma that surrounded 
HIV/AIDS as it emerged in the 1980’s, HIV programs took more of a human rights approach to 
diagnosing and supporting patients with HIV.  Testing was voluntary and on demand of the 
individual patient.  As such, few existing programs integrated HIV activities into routine care 
and few new clinics initiated collaborative TB/HIV activities. 
In 2004, WHO’s Stop TB Department and Department of HIV/AIDS recommended 
strategies to reduce the burden of suffering caused by TB/HIV co-infections.  Their 
recommendations included a shift toward implementing joint TB/HIV activities and 
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encompassed three key activities: national oversight of collaborative TB/HIV activities, activities 
to reduce the burden of TB in HIV patients, and activities to reduce the burden of HIV in TB 
patients.  These recommendations encourage existing TB and HIV programs to expand and 
consider addressing prevention and treatment of the other half of the co-infection.  For 
tuberculosis programs, WHO identified six specific activities to reduce the burden of suffering 
caused by HIV in TB patients. It recommended all tuberculosis patients 1) be tested for HIV and 
2) receive their HIV test result through post-test counseling.  Those patients who are found to be 
HIV-positive should be 3) started on cotrimoxazole as a preventive therapy (CPT), 4) provided 
or referred for HIV care and support, and 5) started on antiretroviral treatment (ART). Finally, 6) 
condoms should be available in TB clinics for all patients.   
 
B. Evidence for collaborative TB/HIV activities 
 
 WHO’s recommended collaborative TB/HIV activities were based on limited evidence 
available at the time of the published recommendation.  From that time, the evidence base has 
grown and is summarized below. 
 
Systematic Review Methods 
 
Identifying literature 
Specific research questions of interest were defined for each recommended collaborative 
activity to reduce the burden of suffering due to HIV in TB patients.  They include: 
 How effective is counseling and testing for HIV in changing behavior and reducing HIV 
transmission among newly diagnosed TB patients? 
 How does providing CPT to newly diagnosed TB patients found to be HIV-positive 
affect risk of mortality? 
 How does providing referral to HIV care and support to newly diagnosed TB patients 
found to be HIV-positive affect risk of mortality and/or adherence to treatment? 
 How does providing ART to newly diagnosed TB patients found to be HIV-positive 
affect risk of mortality?  
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 To what extent have collaborative TB/HIV activities been implemented at the national 
and local or clinic level? 
 
Because TB programs treat patients of all ages, the search included studies of adult and pediatric 
populations.  It included both individual and combined activities as activities may be adopted 
individually or in a step-wise fashion.  Medline was searched collectively for all questions of 
interest using the following search strategy:  
(TB or tuberculosis) AND ((HIV OR (human immunodeficiency virus) OR AIDS OR 
(aquired immune deficiency syndrome) OR (acquired immunodeficiency syndrome)) 
AND ((VCT OR testing) OR ("Trimethoprim-Sulfamethoxazole Combination"[MeSH] 
OR cotrimoxazole preventive therapy OR CPT) OR ("Mental Health"[MeSH] OR 
"Mental Health Services"[MeSH] OR "Social Support"[MeSH] OR "Counseling"[MeSH] 
OR "Self-Help Groups"[MeSH]) OR ("Antiretroviral Therapy, Highly Active"[MeSH]  
OR zidovudine OR lamivudine OR efavirenz OR nevirapine OR stavudine OR ZDV OR 
3TC OR EFZ OR NVP OR d4T)).   
MeSH terms were not used for TB or HIV search terms as using them greatly reduced citations 
returned.  First-line antiretroviral medications as identified by WHO
4 
 were used to complement 
the ART search. Search dates were from 1980 to April 2007, and the search was restricted to 
human studies published in English.  Additional citations were identified from relevant review 
articles.  The grey literature was not reviewed.  Titles and abstracts were reviewed to include 
efficacy studies and reports on the uptake or cost-effectiveness of each intervention, individually 
or in combination.  Because of the lack of randomized-controlled trials, non-controlled trials, 
observational studies, and decision analyses were included. Case reports and case-series of less 
than ten patients were excluded.  Outcomes of interest included death, CD4 count or viral load, 
treatment harms, collaborative activity uptake, and cost-effectiveness.   
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Validity assessment/data abstraction 
Full texts of selected articles were independently reviewed to extract key findings into a 
summary comparison table and to determine study quality.  Because of the small number of 
studies identified, this review includes all studies with mention of study limitations where 
appropriate.   
 
Systematic Review Results 
 Initial searching yielded 1173 citations.  After review of titles and abstracts, eight 
comparative trials were identified that provided information on the efficacy of recommended 
interventions using patient-centered outcomes.  They are summarized in table 1.  Five trials 
examined the efficacy of CPT (with or without HIV testing) while three addressed ART.  No 
trials independently assessed HIV counseling and testing or the effectiveness of referring patients 
for HIV care and support in TB/HIV co-infected populations.  The effectiveness of HIV 
counseling and testing and referral for HIV care and support have been reported in HIV-positive 
populations.  Such studies are briefly reviewed below and give insight into the effectiveness of 
such interventions among patients co-infected with TB and HIV. 
 
Cotrimoxazole preventive therapy 
 Of the citations addressing CPT, only Wiktor, et al. (1999) was a randomized-controlled 
trial of the effectiveness of CPT in HIV-positive patients.  In this study of adult patients in Cote 
d’Ivoire, those taking CPT had a hazard ratio of death of 0.54 (95% CI: 0.38-0.77) compared to 
those in the intervention group
5 
.  This result was seen despite the study being stopped early as an 
unrelated trial of CPT in HIV patients (not specific to TB patients) was published showing net 
benefit of CPT
14 
.  Side effects and adverse effects necessitating stopping treatment were equal 
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Table 1. Comparative studies about effectiveness of collective TB/HIV activities 
Citation Year Location Study type Intervention 
Number 
of pts 
Patient 
characteristics Outcome Result 
Wiktor, et al. 5  
 
1999 
 
 
Cote 
d'Ivoire 
 
RCT 
 
 
Randomized CPT for HIV-
positive patients 
 
771 
 
 
18+yo 
HIV-1+ 
 
Death among TB/HIV co-
infected (10 mo medial follow-
up) 
Hazard ratio: 
0.54 (95% CI: 
0.38-0.77) 
Grimwade, et al. 6  
2005 
 
 
South 
Africa 
 
cohort with 
historical 
controls 
CPT for all TB patients 
 
 
3325 
 
 
13yo+ 
no HIV test  
 
Death among all TB pts (6 mo) 
 
 
14.5% control, 
10.3% CPT 
(p<0.001) 
Mwaungulu, et al.7  
2004 
 
 
 
Malawi, 
Karonga 
District 
 
cohort with 
historical 
controls 
 
CPT for HIV-positive 
members of intervention 
cohort 
 
712 
 
 
 
2mo+ 
70% HIV 
positive 
 
Death among all TB pts (18 
mo) 
 
 
Hazard ratio: 
0.72 (95% CI: 
0.50-1.02) 
 
Chimzizi, et al.8  
 
 
2004 
 
 
 
Malawi 
 
 
 
cohort with 
neighboring 
district 
controls 
HIV-testing for 
intervention cohort and 
CPT for those HIV-
positive 
2342 
 
 
 
1yo+ 
78% HIV 
positive 
 
Death among all TB pts (12 
mo) 
 
 
RR: 0.84 (95% 
CI: 0.78-0.91) 
 
 
Zachariah, et al.9  
 
 
2003 
 
 
 
Malawi, 
Thyolo 
District 
 
cohort with 
historical 
controls 
 
HIV-testing for 
intervention cohort and 
CPT for those HIV-
positive 
1986 
 
 
 
>2 yo 
77% HIV-
positive 
 
Death among all TB pts (12 
mo) 
 
 
Hazard ratio: 
0.76 (95% CI: 
0.69-0.83) 
 
Dheda, et al.10  
 
 
2004 
 
 
 
UK 
 
 
 
cohort with 
historical 
control 
 
Those treated during 
HAART era versus those 
treated before HAART 
era. No mention of CPT. 
96 
 
 
 
23-62 yo 
all HIV-
positive 
 
Death in HAART era vs. pre-
HAART era 
 
 
Hazard Ratio: 
0.18 (95%CI: 
0.06-0.52) 
 
Dean, et al. 11  
 
 
 
2002 
 
 
 
 
UK 
 
 
 
 
retrospective 
cohort 
 
 
 
Thos who received 
HAART vs. those who did 
not. Number of patients 
on CPT not reported. 
 
188 
 
 
 
 
median age 
34 yo 
(range 21-70) 
all HIV-
positive 
1) AIDS-defining illness in 
HAART recipients vs. non-
HAART recipients 
2) Death in HAART recipients 
vs. non-HAART recipients 
1) Risk ratio: 
0.14 (p<0.001) 
 
2) Unadjusted 
risk ratio: 0.27a 
Garcia, et al. 12  
2002 
 
 
Spain 
 
 
retrospective 
cohort 
 
Patients diagnosed before 
and after HAART initiation 
(31 Dec 1996). 
549 
 
  
Death in HAART era vs. pre-
HAART era 
 
Hazard Ratio: 
0.37 (95% CI: 
0.21-0.64) 
Schiffer, et al.13  
 
 
2007 
 
 
 
US 
 
 
 
Decision 
analysis 
 
 
Early vs. late vs. no ART 
 
 
 
- 
 
 
 
- 
 
 
 
All cause mortality 
 
 
 
33 vs. 47 vs. 
147 deaths per 
1000 patients, 
respectively 
 
a
 Author’s unadjusted calculation from figures reported in article 
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between the two groups.  In their analysis, they confirmed the results seen in HIV-positive non-
TB patients supporting the use of CPT for patients with TB/HIV co-infections.  
 Since further placebo controlled trials of CPT for TB/HIV co-infected patients would 
have received ethical criticism, the subsequent four studies were cohort studies completed in 
Africa that used historical or neighboring district control groups that did not receive CPT.  They 
enrolled children and adults of varying ages, and at least 70 percent of TB patients enrolled 
wereHIV-positive.  Results include a risk ratio of death of 0.84 (95% CI: 0.78-0.91), a hazard 
ratio of 0.72 (95% CI: 0.78-0.91), and in the smallest trial (n= 712), a hazard ratio of 0.84 (95% 
CI: 0.50-1.02).
6, 7, 9 
  The fourth trial reported a statistically significant absolute risk reduction of 
4.2 percent for those taking CPT.
8 
  Only two of these observational trials reported adverse 
events.  In the largest trial of over 3,000 patients, 23 people stopped CPT because of perceived 
adverse events including two serious dermatological reactions.  In the other trial to report side 
effects, 2 percent of the study participants reported minor skin rashes that resolved upon stopping 
CPT.  As these were all cohort studies with non-randomized control groups, each is likely 
subject to confounding.  Most notably, the implementation of CPT requires additional training 
and resource input that increases overall quality of care.  This could affect a study outcome that 
would make CPT appear more beneficial than it would be alone. The district that received 
treatment had a long history of working with the sponsoring NGO, likely altering medical norms 
in the community.  Despite these limitations, these trials taken together support the use of CPT in 
patients with TB/HIV co-infections.  
 
Anti-retroviral therapy  
Three citations investigated the role of ART in TB/HIV co-infected patients.  As was 
seen for CPT, ART has been shown highly effective at preventing opportunistic infections and 
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death in HIV-positive patients.
15 
  ART has just started to become available in parts of resource 
poor countries.  As a consequence, very few studies have reported outcomes of ART in TB/HIV 
co-infected patients.  In this review, four were identified.  The first two are retrospective cohort 
studies from patients in the United Kingdom.
10, 11 
  They both enrolled adult TB patients, many of 
whom had known their HIV status for several years.  Dean, et al., report a risk ratio of 0.14 
(p<0.001) for AIDS-defining illness in TB patients on HAART therapy versus those not on 
therapy.  An unadjusted risk ratio of 0.27 for death between the two groups was calculated from 
figures reported in the article.
1
  Dheda, et al., reports a hazard ratio for death of 0.18 (95%CI: 
0.06-0.52) between those taking and those not taking HAART.  As is common in retrospective, 
observational studies, baseline populations differed in these studies and unaccounted for factors, 
such as health systems improvement prompted by the implementation of HAART, likely 
confound the true relationship between treatment and outcome.  Nevertheless, the demonstrated 
benefit is great enough that ART is likely beneficial in these populations.    
 A third, cohort study retrospectively studied 549 cases of extra-pulmonary TB who were 
HIV-positive.
12 
  This analysis compared cohorts before and after 31 December 1996 when 
HAART became available in the country of study.  The hazard ratio of death for those taking 
HAART was 0.37 (95%CI 0.21-0.64).  The study has several potential shortcomings in that there 
were no baseline characteristics of the groups presented, 82 percent of patients were in the no 
HAART group, and DOTS was implemented around the same time as HAART.  Despite the 
strong potential for confounding, the results are consistent with the figures reported in other trials.  
Schiffer and Sterling used a decision analysis to model the effect of ART in TB 
patients.
13 
  They report 33, 47, and 147 deaths per 1000 people in groups initiating HAART 
                                                 
1
 Calculation of unadjusted RR (# of patients who died while taking HAART/total patients taking HAART divided 
by # of patients who died while not taking HAART/total # of patients not taking HAART) =(3/85)/(13/98)=0.27 
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early (during the first two months of TB treatment), initiating HAART late (after the first two 
months of TB treatment), and not starting HAART.  In their model, the majority of deaths in the 
late and no HAART groups were secondary to tuberculosis or HIV.  However, a significant 
number of deaths in the early HAART group are due to immune reconstitution inflammatory 
syndrome (IRIS).  Nevertheless, the decision analysis clearly favors starting HAART over not, 
and also supports starting HAART early after TB diagnosis rather than waiting until patients are 
stable on their anti-tuberculosis regimen. 
 In addition to the three citations evaluating ART in TB patients above, one larger (n=439) 
retrospective cohort study from Malawi and six additional small, cohort studies (n=20 to 92) 
were identified.  The retrospective study from Malawi examined survival at 6 and 12 months 
between children under age 12 taking ART who had current TB diagnoses, a TB diagnosis in the 
past two years, and non-TB diagnoses.  Researchers found no difference in death rates between 
these groups with the probability of survival being 0.86, 0.86, and 0.88, respectively.
16 
  Because 
this was a retrospective cohort study drawing on routine, clinic-collected data and the difficulty 
of diagnosing TB in HIV-positive children, a substantial portion of patients may have been 
misclassified regarding their TB status.  However, the results suggest that children given ART 
have a high likelihood of survival irregardless of TB status. 
The other six studies that were conducted in Spain, South Africa, Thailand, and Brazil 
report undetectable HIV viral load rates of 62.5 to 94.1% in TB/HIV patients on ART.
17-22 
   In 
these studies, very few, if any, patients died over a maximum follow-up of four years.  This low 
death rate supports ART efficacy in TB/HIV co-infected patients.  Up to 35 percent of patients 
experienced minor side effects of treatment, and some required stopping or changing treatments 
regimens. 
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Referral for HIV care and support 
The literature search returned no citations that quantified the effect of referring patients 
for HIV care and support among TB/HIV co-infected patients.  Such programs are diverse and 
good evaluation measures are lacking.   The only studies identified were descriptions of the role 
that community HIV care and support have played in parts of Malawi.
23 
   In their community, 
volunteer resources play an integral part in caring for TB/HIV co-infected patients including  
operating community gardens, providing child/orphan care, monitoring side-effects, providing 
nutritional support, and directly caring for patients in their homes.  Authors were also clear to 
emphasize the importance of including community members in the development and initiation of 
community HIV care and support activities and the importance that community resource groups 
do not duplicate activities that should be the responsibility of clinic staff. The importance of HIV 
care and support activities is hard to measure, but such reports emphasize the importance of 
providing community support for patients with TB, HIV, or both.  
 
Voluntary counseling and testing for HIV 
While no studies meeting inclusion criteria addressed the effectiveness of VCT in 
reducing the burden of HIV in patients with TB, more research is available on the usefulness of 
VCT in HIV-positive populations.  One RCT and several meta-analyses of smaller studies 
suggest that VCT may reduce high-risk behaviors.  The RCT compared patients who received 
VCT to patients receiving routine health information in Kenya, Tanzania, and Trinidad.
24 
  It 
found that those receiving VCT had lower rates of unprotected intercourse and intercourse with 
non-primary partners than the control group.  When the group receiving routine health 
information was provided VCT, their rates of high-risk behaviors were reduced to a similar rate 
as the initial VCT group.  In post-hoc analysis among those who received VCT, HIV-positive 
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individuals had lower rates of high-risk behaviors compared to HIV-negative patients.  This 
suggests that being diagnosed with HIV may change high-risk behaviors more than if one 
undergoes VCT but tests negative. 
Two meta-analyses show similar trends toward effectiveness of VCT in reducing high-
risk behavior, at least in HIV-positive populations.
25, 26 
  The first included 27 studies from the 
US, Africa, and Europe and reported that HIV-positive patients and discordant couples were 
significantly more likely to use condoms and less likely to have unprotected intercourse than 
untested patients.  The rate of high-risk behavior for HIV-negative patients was not statistically 
different, but also not higher, than untested patients.
25 
  The second meta-analysis included 11 
trials from the US.  It reported that HIV-positive patients who underwent VCT had 53 percent 
less unprotected anal or vaginal intercourse than HIV-negative patients after VCT (95% CI 45 to 
60 percent).
26 
   
Such studies suggest that VCT may be effective at reducing high-risk behaviors among 
HIV-positive patients and do not show an increase in high-risk behavior among HIV-negative 
patients.  The applicability of such trial data to the widespread rollout of VCT has been 
questioned, however.  One of the hurdles to these studies’ generalizability is the concern that 
people who volunteer for VCT effectiveness trials are often at high risk for HIV.
27 
  Patients who 
know they are at high risk for HIV may change their behavior after VCT in a different way than 
those who are at low risk for HIV.  When such VCT programs are scaled up to population levels, 
patients on the whole are likely to be at lower risk and have lower rates of HIV.  The 
effectiveness of VCT in changing behavior may be more limited than the studies suggest. 
Patients presenting to TB clinics in sub-Saharan Africa are generally at high risk for HIV.  
In many places, up to 72 percent of TB patients are HIV-positive.
28, 29 
  Such a population with a 
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high risk of HIV infection may be more similar to some of the VCT trial populations than the 
general public.  As a result, trial outcomes may be more generalizable to this group with high 
risk for HIV than the population at large.  In such instances it seems reasonable to extrapolate the 
results of the VCT effectiveness trials to such populations, especially for those who test HIV-
positive.  To truly measure effectiveness in TB populations, however, separate trials would have 
to be completed, but completing such trials would not be ethical under the current guidelines to 
screen all TB-positive patients for HIV.   
 
C. Monitoring, evaluation, and uptake of collaborative TB/HIV activities 
 
Monitoring and evaluation of activities are integral to all interventions.  WHO has 
published guidelines to guide the monitoring and evaluation process of collaborative TB/HIV 
activities.
30 
  As described in WHO recommendations, there are two parts to program evaluation.  
Monitoring refers to routine analysis of clinic performance using regularly gathered information 
to evaluate the extent to which a program is achieving its stated goals.   Evaluation is an episodic 
process of evaluating the extent to which results that can be attributed to an intervention or 
program and can include results of program monitoring in addition to other specially collected 
data.  Often evaluation of a program is subdivided into evaluating the processes involved in 
implementing the program and evaluating the outcome of the program.  While this present 
analysis is at its core an outcome evaluation, it can contribute to the understanding of the 
collaborative activity rollout process and the process of clinic evaluation. 
WHO identified seven key indicators to measure collaborative TB/HIV activities. They 
are listed in table 2.  Six of these are based upon the six activities listed above.  The seventh is 
the proportion of HIV-tested patients who are found to be HIV-positive. 
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Table 2. Indicators of uptake of activities to reduce the burden of HIV/AIDS in TB patients
30 
 
 
Indicator 
 
Numerator 
 
Denominator 
 
Periodicity 
Proportion of registered 
TB patients tested for HIV 
# of registered TB patients tested 
for HIV 
# of total TB patients 
registered 
Quarterly 
Proportion of registered 
TB patients who are HIV-
positive 
# of registered HIV-positive TB 
patients  
# of total TB patients 
registered 
Quarterly 
Proportion of HIV-tested 
patients who receive post-
test counseling 
# of patient who are tested for 
HIV and receive post-test 
counseling 
# of total TB patients 
tested for HIV 
 
Quarterly 
Availability of free 
condoms at TB services 
# of TB facilities where condoms 
are distributed 
# of total TB facilities Annually 
 
Proportion of HIV-positive 
TB patients who receive 
CPT 
# of HIV-positive patients who 
receive at least one dose of CPT 
during their TB treatment 
# of total HIV-
positive TB patients 
Quarterly 
Proportion of HIV-positive 
TB patients who receive 
HIV care and support 
services 
# of HIV-positive patients who 
are referred to HIV care and 
support during their TB treatment 
# of total HIV-
positive TB patients 
Quarterly 
Proportion of HIV-positive 
TB patients who receive 
ART 
# of HIV-positive patients who 
start ART or continue previously 
initiated ART during their TB 
treatment 
# of total HIV-
positive TB patients 
Quarterly 
 
Since WHO recommended the implementation of collaborative TB/HIV activities, uptake 
has varied widely by country.  In its 2007 report, WHO reports the worldwide uptake of 
collaborative TB/HIV activities.
1 
  Reported figures are based on those submitted by national 
tuberculosis programs and their clinics, and, unfortunately, the reporting practices and rigor may 
vary widely by country.  WHO specifically reports on the activities of 63 high-burden countries: 
58 countries with >1 percent of the population HIV-positive plus 5 countries with a high 
percentage of TB patients with HIV.  While rates of testing and reporting of testing have been 
increasing since 2002 (see Figure 1), globally only 6.7 percent of TB patients are tested for HIV 
and it is estimated that only 13 percent of patients with TB/HIV co-infections have been 
identified.  Twenty-three percent of tested TB patients worldwide are HIV positive.  Among  
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Figure 1. Collaborative TB/HIV activities, 2002–2005.1  
  
Bars show the numbers (in thousands) of TB patients that were tested for HIV, found to be HIV-
positive, given CPT, started on ART in four consecutive years. The numbers of countries 
reporting data in each year are given above the bars. 
 
TB/HIV co-infected patients, it is estimated that between 0.5-18 and 1-55 percent are started on 
CPT and ART, respectively.    
Africa contains 37 of the world’s 63 high burden of TB countries (see Figure 2).  Of these 
37 countries, only 21 reported the percentage of TB patients who had been tested for HIV in 
2005.  Uptake of collaborative TB/HIV activities in Africa as reported by countries to WHO is 
summarized in table 3. Overall in the Africa region in 2005, an estimated 11 percent of TB 
patients were tested for HIV, and 51 percent of those tested were HIV-positive.  Of those who 
were TB/HIV co-infected, 82 and 29 percent of the HIV-positive patients were reported to have 
started CPT and ART, respectively.
1 
  
Several authors have reported uptake rates of collaborative TB/HIV activities on a local 
or regional level to provide an idea of the acceptability and feasibility of such activities in 
resource poor settings and in settings of high TB/HIV co-infection rates. One of the first reports 
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Figure 2. Geographical distribution of HIV-positive TB cases, 2005.
1
  
 
For each country or region, the number of incident TB cases arising in people with HIV is shown 
as a percentage of the global total of such cases. AFR* is all countries in WHO African Region 
except those shown separately; AMR* excludes Brazil; EUR* excludes the Russian Federation; 
SEAR* excludes India. 
 
of HIV counseling and testing was by Abouya, et al. (1998), who reported an HIV-testing 
acceptance rate of 91.8 percent in eight TB clinics in Cote d’Ivoire between July 1994 and June 
1996.  43.2 percent of tested patients were diagnosed with HIV.  They achieved these rates 
despite not offering any HIV treatment at that time.
31 
   
 Initial testing rates in local programs in Malawi varied in their success.  Zachariah, et al. 
(2006) report on collaborative TB/HIV activities in a rural district in Malawi between January 
and December 2000.  In two local hospitals, 91% of TB patients accepted referral to the 
hospitals’ VCT unit.  Eighty-seven percent received post-test counseling where 77 percent 
learned they were HIV-positive.  Ninety-four percent started CPT.
32 
  When broader activities 
were initiated in Malawi, Chimzizi, et al. (2004) report testing rates of 59 percent in 15 diverse 
hospitals throughout the country.  These rates varied widely by district (range 40 to 96 percent). 
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Table 3.  Collaborative TB/HIV activities in 2005 in Africa as reported by WHO
1  
 
% of 
world 
TB/HIV 
cases
b 
 
Estimated 
new TB 
cases
c 
 
Total TB 
cases 
identified
d
 
TB patients 
tested for 
HIV 
 
Tested TB 
patients HIV-
positive 
 
Identified 
TB/HIV co-
infected 
patients started 
on CPT 
Identified 
TB/HIV co-
infected 
patients started 
on ART 
 % (n) (n) (n) % (n) % (n) % (n) % 
South Africa 19 284538 302467 67998 22 35299 52 35299 100 11654 33 
Nigeria 8 371642 66848 7013 10 1230 18 0 0 0 0 
Kenya 7 219582 108401 15494 14 8899 57 7119 80 1779 20 
Zimbabwe 5 78187 54891 - 0 - - - - - - 
Mozambique 5 88533 33718 - 0 - - - - - - 
Zambia 4 70026 53267 1082 2 614 57 0 0 418 68 
Tanzania 4 131078 64200 2521 4 1274 51 514 40 359 28 
DRC 4 204977 99558 1885 2 386 20 284 74 3 1 
Uganda 4 106285 41809 3306 8 1676 51 0 0 0 0 
Ethiopia 3 266288 125135 3211 3 1321 41 1166 88 388 29 
Malawi 3 52751 27610 12243 44 8447 69 7747 92 4156 49 
Code d'Ivoire 2 69417 20026 4079 20 1551 38 590 38 216 14 
Swaziland 1 13029 8864 - 0 - - - - - - 
Remainder of 
Africa 10 
 
572582 
 
180006 9947 6 4557 46 526 12 180 4 
Africa Total 80
a 2528915 1186800 128779 11 65254 51 53245 82 19153 29 
a
Not equal to total due to rounding. 
b
From Figure 6, pg. 27. 2007 WHO TB Report. 
c
From Table A2.1, pg.174. 2007 WHO TB Report. 
d
From Table A2.2 pg.175. 2007 WHO TB Report. 
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Of the patients who tested positive 97 percent started CPT (range 64 to 100 percent).  Factors 
that the authors cite as reasons for higher testing rates include well organized and enthusiastic 
staff, no stockouts of supplies, full time counselors, and dedicated counseling and testing rooms 
in the facility.
33
 
 The feasibility of collaborative TB/HIV activities has also been reported at the national 
level.  Several African countries have made substantial efforts to implement collaborative 
TB/HIV activities; four of which have been highlighted by WHO tuberculosis reports.  In 2002 
and 2003, Malawi tested 8 and 15 percent of its TB patients, respectively, and in 2003 provided 
CPT to 87 percent of the patients who tested positive.
34 
  As a complement to its rollout of 
antiretroviral programs, Malawi started nationwide HIV screening of TB patients in 2004. 
Initially 24 percent of TB patients were tested for HIV, and 72 percent were found to be HIV-
positive.  By the third quarter of 2005, at least 43 percent of TB/HIV co-infected patients started 
ART.
28, 29 
 In 2005, 44 percent of TB patients nationwide were tested for HIV, and nearly half of 
TB/HIV co-infected patients start ART. 
In March 2005, Kenya implemented a nationwide program to rapid test TB patients. By 
the third quarter of 2005, 32% of TB patients were tested in the country. This doubled to 64% 
one year later (3
rd
 quarter 2006). Of the 54% of patients found to be co-infected, 80% were 
given CPT and 30% started ART. 
1 
 
Rwanda rolled out nationwide program starting in 2004 when 46% of patients were tested. 
By the third quarter of 2006, 81% were tested. Of the 38% of TB patients who tested HIV 
positive in 2006, 43% were given CPT and 31% started ART.
1  
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 Finally, Zambia implemented collaborative TB/HIV activities in 2006 and testing 
increased from 2 to 52% by the third quarter. Of the 56% of TB patients who were co-infected 
with HIV, 29% were given CPT and 33% started ART.
1 
   
 
III. Methods 
 
Clinic profiles and integrated TB/HIV activities 
 
 Data were collected from all patients at 14 tuberculosis clinics in Kinshasa, Democratic 
Republic of Congo.  Of these clinics, 1 is public (a hospital) and 13 affiliated with religious 
institutions or denominations.  They were chosen among the 92 TB clinics present in the city of 
6.5 million people because they had a significant patient population, enthusiasm for expanding 
patient care, and the space needed to implement collaborative TB/HIV activities.  
 All fourteen study clinics treated TB patients.  In preparation for collaborative TB/HIV 
activities, TB clinic staff underwent a four-day training on HIV testing and counseling and 
opportunistic infections.  Clinics initiated collaborative TB/HIV activities between January 18 
and February 27, 2006.  Monthly meetings were held with program and clinic staff to discuss 
concerns and hurdles to implementation and care. 
 
Study design and data collection 
 
 Descriptive analysis of uptake of collaborative TB/HIV activities is reported from 
analyzing routine clinic data collected by TB clinic staff on modified TB treatment cards 
included in Appendix A.  This information includes routine TB data but also date of pre-test 
counseling, HIV testing, post-test counseling, initiation of CPT and ART, and referral to HIV 
support programs.  These data, with patient identification removed, were collected from clinic 
registers and transferred to an electronic database by research staff.  For acceptance of HIV 
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testing, HIV test results and referral for HIV care and support, TB treatment cards included 
boxes to check for accepting or denying an HIV test, for HIV-positive, negative, or 
indeterminate status, and for being referred or not.  For the remaining uptake indicators, the 
activity was considered completed if a date was entered on the TB treatment card for each 
activity. 
 
Study population and clinic procedures 
 
All patients presenting to the study clinics were screened for tuberculosis using sputum 
microscopy, and physician clinical judgment if smear negative.  If found to have TB, clinic staff 
entered patients into the TB registry and started them on TB treatment according to the national 
DOTS program guidelines.  They were offered HIV counseling and testing by the TB nurse at 
the time of diagnosis, and if they initially refused, the offer was repeated after one and two 
months of TB treatment or the patient was tested upon his or her request.  All testing was done 
using Determine HIV-1/HIV-2 (Abbott Laboratories, Tokyo, Japan) and Uni-Gold
TM
 HIV-
1/HIV-2 (Trinity Biotech, Wicklow, Ireland), according to WHO strategy II for antibody HIV 
testing {P1-#9}.  HIV-positive TB patients were offered cotrimoxazole, 480 mg twice daily for 
adults and 6-8 mg/kg for children, unless contraindications were present.  Infected patients were 
referred to a local HIV care and support program if available, offered ART at the clinic if 
available, or referred to a local HIV clinic. If patients obtained ART, the HIV clinic also 
managed their CPT. 
 
Outcome measures 
 
This study measured six of the seven WHO indicators for collaborative TB/HIV activities: 
1) the acceptance of HIV testing over all TB patients, 2) the percent of tested patients who are 
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HIV-positive, 3) the percent of tested patients who received post-test counseling, 4) the percent 
of HIV-positive patients who started cotrimoxazole preventive therapy, 5) the percent of HIV-
positive patients referred for HIV care and support, and 6) the percent of HIV-positive patients 
who started anti-retroviral therapy. 
35 
  Per WHO recommendations, these six indicators are to be 
recorded continuously, extracted at the end of TB treatment, and reported to the national TB 
program quarterly with routine TB data.  This allows for patients who are tested for HIV any 
time during their treatment to be measured.  Following WHO recommendations, patient data 
were extracted at the conclusion of TB treatment, with patients divided into quarterly groups 
based on their registration date.  WHO recommends that the seventh indicator, the availability of 
free condoms at tuberculosis services, be measured annually, and was therefore not included in 
this analysis.     
 
Statistical analysis 
 
 Descriptive statistics were performed to assess WHO indicators.  Patients were 
categorized by registration date into three month blocks indicating in which quarter of the 
program they were registered.  WHO indicator performance collectively and for individual 
clinics was plotted by quarter after program implementation and a line of best fit was drawn 
using a linear prediction model.  One way analysis of variance tested for significant changes in 
indicators by clinic over time using a two sided alpha of 0.05.  Analysis was performed using 
Stata 9.2 (College Station, TX). 
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IV. Results 
 
Study population 
 
Between January 2006 and January 2007, the fourteen TB clinics registered 3,521 
tuberculosis patients for an average of 252 patients per clinic (range 80 to 450).  Over seventy-
five percent of patients were adults with visible BCG scars and new cases of pulmonary 
tuberculosis, of which seventy-three percent were smear positive (Table 4).  The average age was 
33 years with 84.2 percent of patients being older than eighteen and 2.8 percent under age 2. 
Slightly more men than women were enrolled: 52.2 and 47.4 percent, respectively. 
 
Table 4. Patient characteristics of all registered patients (n=3521) 
Characteristic Mean (s.d.)  
Or Percent 
Age (yrs) 33.2 (35.2) 
% Adults (≥18 years) 84.2 
% Male 52.2 
% With visible BCG scar 78.1 
% Pulmonary TB 79.5 
% Smear + if Pulmonary 73.1 
% New case 
Retreatment 
Failure 
Resumption of treatment 
88.2 
8.8 
0.8 
1.1 
Uptake of HIV counseling and testing 
 
Overall 3,173 (97.6 percent) of the 3,521 registered tuberculosis patients were offered an 
HIV test and 93.3 percent of all registered patients accepted an HIV test (Figure 3).  While 
consistently over 90 percent of patients were tested for HIV, rates trended upwards over time 
(Figure 4) from 92.8 percent in the first quarter of clinic operation to 96.9 in the final quarter 
(p=0.29).  98.8 percent of those who accepted testing did so at the initial offer of testing during 
tuberculosis clinic registration.  Of the patients who accepted an HIV test, 95.8 percent returned 
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for post-test counseling.  Unlike testing rates, return for post-test counseling rates decreased over 
time from 96.6 percent in the first quarter to 92.3 percent in the final quarter (p=0.031).   
When viewed by clinic, the percentage of patients who accepted HIV testing and post-test 
counseling varied substantially and trends in rates of testing and counseling differed between 
clinics. All clinics tested more than 90 percent of patients except four which tested 65.0, 82.4, 
86.1, and 86.2 percent.  Eight clinics had initial testing rates over 90 percent and sustained them 
over the year.  One clinic increased its testing rate from 76.9 percent in the first quarter to 95.6 
percent by the third (p=0.0024).  Two clinics had statistically significant declines in testing rates 
over time from 100 to 71.4 percent (p=0.018) and from 97.2 to 87.5 percent (p=0.048).  Two  
 
Figure 3. Number of patients participating in each TB/HIV collaborative activity 
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* Values for rates of initiation of CPT and ART and referral for HIV care and support are 
calculated for the proportion of patients who are HIV-positive 
 
100%      97.6%     93.3%     95.8% 
 
 16.7%      81.5%*    41.2%*     6.9%* 
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Figure 4. Percent of patients receiving each of the six collaborative TB/HIV activities  
by quarter. 
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additional clinics had rates that trended downward from 96.7 to 88.0 percent (p=0.072) and 
from72.7 to 60.7 percent (p=0.27).   
Thirteen clinics had more than 90 percent of patients tested for HIV return for post-test 
counseling. One of these clinics saw a decline in counseling rate to 41.2 percent by the third 
quarter (p<0.001).  Another’s counseling rate trended downward to 80.0 percent by the third 
quarter (p=0.22).  Both of these clinics still counseled over 90 percent of patients during the 
study period.  The final clinic’s counseling rate trended downward from 84.6 to 73.3 percent 
between the first and third quarter (p=0.59).   
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HIV positive rate 
 
Overall, 525 TB patients tested positive for HIV (16.7 percent; 95% CI: 15.4-18.0).  This 
rate had a slight, non-significant decrease over time from 17.6 percent in the first quarter to 14.5 
percent in the fourth (p=0.31).    The range of HIV-positive rates in TB patients tested by clinic 
was 8.8 to 33.3 percent.  Two clinics showed substantial, but not statistically significant, 
increases in their HIV-positive rates over time.  The rate in the clinic with the most HIV-positive 
patients trended upward over time from 28.0 percent in the first quarter to 40.0 percent in the 
third quarter (p=0.74) as did the rate of the clinic with the second highest percent of HIV-
positive patients from 18.7 percent initially to 50.0 percent in the third quarter (p=0.071).  
However, in the third quarter this clinic had only 10 patients compared to 90 in each of the 
previous two quarters.  Three clinics saw trends toward decreases of about ten percent in their 
HIV-positive rates between the first and third quarters from rates around to 20 percent to around 
10 percept (p=0.16 to 0.39). 
 
Care for TB/HIV co-infected patients 
 
 Of the 525 patients co-infected with TB and HIV, 81.5 percent started CPT, 41.2 percent 
were referred for HIV care and support, and 6.9 percent started or continued ART.  Overall, rates 
of CPT initiation trended downward from 85.6 percent the first quarter to 72.0 percent the fourth 
quarter (p=0.062).  Ten clinics achieved an average CPT initiation rate greater than 80 percent, 
and the remaining four averaged over 60 percent.  Only five clinics maintained rates of over 80 
percent over time while one increased from 77.8 percent in the first quarter to 100.0 percent in 
the third quarter (p=0.43).  Two clinics had significant decreases in CPT initiation from 100 to 
50 percent (p=0.041) and 88.9 to 42.9 percent (p=0.010).  Five clinics showed declining trends 
from initial rates near or above 80 percent to rates ranging from 42.9 to 68.8 percent by the third 
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quarter (p=0.13-0.65).  The final clinic had consistent average near 70 percent.  Of the 92 
patients who did not begin CPT, 28 were already taking ART and would thus be prescribed CPT 
by their HIV clinics, three refused treatment, two had contraindications, and four were followed 
elsewhere.  Data was missing for the remaining 55, 10.5 percent of co-infected patients. 
 Referral of TB/HIV co-infected patients for HIV care and support occurred in 41.2 
percent of patients.  This number consistently increased over time from 32.3 percent of patients 
being referred the first quarter to 68.0 percent being referred the fourth quarter (p=0.001).  Four 
clinics averaged referring over half of their patients, three of which showed increases in referral 
rate from between 23 to 40 percent (p<0.001, 0.018, and 0.065, respectively).  The remaining ten 
clinics referred patients much more sporadically, with one clinic never making a referral.  
Thirty-nine patients (6.9 percent) received ART after TB registration.  Of these, 28 (72 
percent) had initiated ART before entering TB treatment.  Ten patients from one of six clinics 
received ART as a consequence of HIV testing by TB clinics.  Initiation of ART did not change 
over time (p=0.57), and when viewed by clinic was sporadic with only one clinic having a non-
significantly increasing rate over time from 7.1 the first quarter to 42.9 the third quarter (p=0.15).  
All of this clinic’s patients started ART before enrolling in TB treatment.   
Rates of collaborative TB/HIV activity uptake by clinic 
 Examining individual clinics with regards to rates of uptake of collaborative TB/HIV 
activities demonstrated variation among clinics.  Three clinics performed well, consistently 
providing HIV testing and post-test counseling to over 90 percent of their patients and starting 
more than 80 percent of the HIV-positive patients on CPT.  Two of these clinics substantially 
increased their referrals for HIV care and support over time as well from 21.4 to 56.5 and 72.7 
to93.4 percent (p=0.0001 and 0.064, respectively).  One clinic had substandard performance. Its 
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rate of HIV testing, post-test counseling, and CPT initiation all decreased or trended downward 
from 100 to 71.4 percent (p=0.017), 85.7 to 50 percent (p=0.41), and 100 to 50 percent (p=0.041), 
respectively, between the first and third quarters.  One clinic improved in some indicators but 
worsened in others.  It showed an increase between the first and third quarter in its rate of HIV 
testing (76.9 to 95.6 percent, p=0.002) and a higher trend in the number of patients who were 
taking ART (7.1 to 42.9 percent, p=0.14).  Even though the rate of HIV positive patients trended 
down from 20.3 to 10.8 percent (p=0.32), the percent of patients starting CPT also trended 
downward from 78.6 in the first quarter to 42.? in the third (p=0.26).  The remaining clinics 
showed varied improvements or declines in performance of up to two indicators over time.  An 
example of summary graphs of selected indicators for an individual clinic is shown in Figure 5.   
 
V. Discussion 
 This study was the first to examine uptake of collaborative TB/HIV activities in the DRC 
under routine clinic conditions.  The results demonstrate that rollout of collaborative activity at 
TB clinics in Kinshasa, DRC, can be successful.  Over ninety percent of newly enrolled TB 
patients accepted an HIV test and returned for post-test counseling.  The HIV positive rate 
among TB patients was similar to WHO estimates.
1  
Over eighty percent of HIV positive patients 
initiated CPT.  Rates for referral for HIV care and support were lower, but increased over time.  
Only initiation rates of ART remained low throughout the study period.   
 Such rates are comparable to those in other areas of Africa with higher rates of HIV 
infection among TB patients (greater than 40 percent).
31-33 
  This study demonstrates that high 
rates of collaborative activities can be achieved in areas with relatively low HIV prevalence in 
the general population where the perceived importance of testing for HIV may be lower.  In  
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Figure 5. Example graphs detailing uptake of collaborative TB/HIV activities at one TB clinic, 
overall and with selected indicators by quarter. 
0
20
40
60
80
100
%
H
IV
 te
st
 o
ffe
re
d
H
IV
 te
st
 a
cc
ep
te
d
R
ec
ie
ve
d 
po
st
-te
st
 c
ou
ns
el
in
g
H
IV
-p
os
iti
ve
S
ta
rte
d 
C
P
T
H
IV
 c
ar
e 
an
d 
su
pp
or
t r
ef
er
ra
l
S
ta
rte
d 
A
R
T
indnum ber
Uptake of collaborative TB/HIV activities
 
5
0
6
0
7
0
8
0
9
0
1
0
0
P
e
rc
e
n
t
1 2 3
Quarter
Percent accepting HIV test by quarter
 
5
0
6
0
7
0
8
0
9
0
1
0
0
P
e
rc
e
n
t
1 2 3
Quarter
Percent receiving post-test counseling by quarter
 
5
0
6
0
7
0
8
0
9
0
1
0
0
P
e
rc
e
n
t
1 2 3
Quarter
Percent starting CPT by quarter
 
5
0
6
0
7
0
8
0
9
0
1
0
0
P
e
rc
e
n
t
1 2 3
Quarter
Percent receiving referral for HIV care and support by quarter
 
I 
 28 
addition, during the study period, these fourteen clinics tested more patients than were tested in 
the whole of the DRC during the previous year.  In 2005, the national TB program reported that 
1,885 TB patients were tested for HIV (1.9 percent of TB patients in the DRC).  Of them, 386 
tested HIV-positive (20 percent), 284 initiated CPT (74 percent) and 3 started ART (1 percent).
1 
 
  There are several potential reasons for the high uptake of collaborative activities in these 
clinics.  First, from the patient perspective, counseling and testing for HIV was convenient 
because it occurred at the start of TB treatment and was done in the TB facility by TB staff.  The 
immediate availability of the HIV test simplified the testing process for the patient by 
eliminating the cost for transportation to another facility and preventing a second clinic visit to a 
separate facility with different medical staff. 
Second, the clinics chosen to participate in the program were selected based on 
enthusiasm and infrastructure.  Motivated staff likely contributed to the acceptance of new clinic 
procedures and responsibilities and subsequent testing and treatment of patients.  Presence of 
space for the increased workload of pre- and post-test counseling facilitate program 
implementation.  While this study shows that rollout of collaborative TB/HIV activities in TB 
clinics is feasible, not all TB clinics nationwide might have the motivated staff or available 
infrastructure to expand their services to the same degree.  As a result, one would expect 
expanded rollout performance to be less successful in other settings.  
 Third, the rollout of these programs occurred with international assistance and guidance.  
As is often the case in low resource settings, material and staff resources are often of limited 
supply due to limited financial resources.  Rollout of collaborative activities was done in a 
variety of established public and private TB clinics that report to the DRC’s national tuberculosis 
program.  These clinics rely on private agencies or the government for their funding.  For the 
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rollout of collaborative TB/HIV activities, no additional clinic staff were hired but outside 
funding contributed to the program.  International aid provided funding for supervision of 
activity rollout, training, cotrimoxazole, monitoring and evaluation of the rollout, and support for 
formation of support groups.  In January 2007, just as the last data in this analysis were 
becoming available, responsibility for the program was shifted to the national tuberculosis 
program.  Unfortunately, in the subsequent months, some clinics experienced stockouts of HIV 
tests and cotrimoxazole, contributing to observed decreased rates of CPT initiation.  
 International assistance also contributed to the development of HIV care and support 
referral services.  Upon implementation of collaborative TB/HIV activities, few agencies existed 
to which patients could be referred for HIV care and support.  Often the ones in existence already 
had a full patient load and were reluctant to take on additional patients.  Only one clinic initially 
referred over half of its patients for HIV care and support.  During the implementation of 
collaborative activities at the TB clinics, HIV support groups were organized by TB clinics, 
increasing the possibility for referral of patients for care and support.  Such local group 
formation significantly increased referral rates at three of the TB clinics  Unfortunately, the 
referral activities at the remaining clinics were sporadic and suboptimal and are a point of further 
attention, study, and improvement.  
 Finally, political unrest did not impact the uptake of collaborative TB/HIV activities as 
was feared.  The DRC is a country that has had a long history of civil war and political unrest.  
When this program began in January 2006, the population had just approved a new constitution 
that allowed for the first presidential elections in 40 years to occur in July during the second 
quarter of collaborative activities.  After the elections there were periods of sporadic violence 
between rival political parties in Kinshasa.  A run-off election in October 2006 declared a winner, 
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which was also followed by occasional political violence until March 2007.
36 
  During such times, 
it is conceivable that collaborative activities may decrease as patients may be nervous about 
leaving their homes or being in public, supply lines for HIV tests or cotrimoxazole may be 
interrupted, or clinics may have to close for security reasons.  During the time of the study, no 
clinics closed because of violence.  Numbers of people presenting to TB clinics were constant.  
While rates of CPT initiation did decrease slightly over time, there is no direct evidence that 
political unrest significantly contributed to this decline. 
In this analysis, uptake measures for all clinics were first analyzed collectively.  Uptake 
trends were stable with a slight increase in acceptance of HIV testing and slight decreases in 
post-test counseling and initiation of CPT.  Referral for HIV care and support substantially 
increased over time.  As can be expected, when clinics were looked at individually, differences 
among clinics became apparent.  The fourteen clinics selected for implementation of 
collaborative activities were a diverse group.  Several clinics performed well on all indicators 
except initiating ART while others performed below average in their HIV testing rates, post-test 
counseling, and CPT initiation.  The referral for HIV care and support between clinics was very 
variable.   Five clinics consistently referred substantially more patients for care and support than 
the remaining nine clinics.  Some clinics’ performance improved over time while others’ 
performance declined.   
The poorer uptake of collaborative TB/HIV activities in two clinics and the high HIV 
positive rate in an additional clinic stood out.  The first of these TB clinics was located in one of 
the larger referral hospitals in the area.  As such, it had the highest HIV-positive rate among any 
of the clinics.  This clinic also happened to have the smallest number of TB patients of any in the 
study (n=80).  Most likely, the low rates of uptake in this study were due to the added 
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responsibilities of the clinic staff in the referral hospital setting.  They likely were not as 
motivated about implementing collaborative TB/HIV activities to the same degree as many 
health care clinics that treat patients from a single community.  Study staff also found it hard to 
motivate the nurses at a second clinic to routinely offer and test TB patients for HIV.  As a result, 
that clinic had the lowest rates of HIV testing of all of the clinics.  A third clinic had the second 
highest HIV-positive rate at 23.6 percent which increased from 18.7 percent in the first quarter to 
50 percent in the third (p=0.07).  The explanation for this increase is unclear, but clinic staff 
suggested it may be due to the clinic’s proximity to a major rail station and the anonymity that 
such a setting might provide. 
Only one other group has published data examining uptake of activities by clinic.
33 
 They 
reported an evaluation of collaborative activities in one quarter after rollout.  The fifteen clinics 
they evaluated also had heterogeneous clinic characteristics, sized and affiliations.  They had 
lower and variable rates of HIV testing by clinic (59 percent tested, range 40 to 96 percent), but 
high rates of CPT initiation across clinics (97 percent started CPT, range 64 to 100 percent).     
Periodic monitoring provides crucial information to programs.  The above findings 
highlight the importance of monitoring and evaluating programs but also evaluating the 
performance of individual clinics.  Analyzing data on the individual clinic levels allows for 
tailoring of interventions and education to specific clinic situations.  In this study, most clinics 
had very high rates of HIV testing, counseling, and CPT initiation.  A large part of this success 
was likely do to the motivation of clinic staff.  Showing them outcomes of their hard work can 
help to perpetuate future success in those clinics.  All clinics regardless of performance can 
benefit from such attention and motivation.  For example, as seen in the clinic demonstrated in 
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Figure 3, rates of HIV testing and referral for HIV care and support trended upwards over time, 
and the clinic staff should be congratulated for their efforts.   
Periodic assessment also provides an opportunity to discover clinics that are deficient in 
their performance and intervene to improve rates of uptake activities. It is a springboard for 
discussion of ways to improve and can be used as the background or baseline information in 
quality improvement activities (e.g. Plan, Do, Study, Act cycles).
37 
  However, rates of CPT 
initiation trended downward.  Knowing this trend, clinic staff can hypothesize the reason for the 
decline, and quality improvement measures can be taken to reverse the trend in CPT initiation.  
As another example, the rates of CPT initiation in the clinic shown in figure three trended 
downward.  Knowing this trend, clinic staff can hypothesize the reason for the decline, and 
quality improvement measures can be taken to reverse the trend in CPT initiation.  Such clinic 
examination can also provide comparative data to demonstrate what other clinics are achieving 
and to identify nearby clinics that can be used as models, training sites, or sites with which a 
clinic could swap staff to promote improvement.   
Data obtained by individual clinic monitoring can also be used to target training 
resources and motivational activities.  Clinics that perpetually perform well during routine 
monitoring and periodic evaluations likely do not need frequent oversight, motivation, and 
intense contact with the oversight body.  Rather, the oversight body’s limited resources can be 
more effectively spent with poorer performing clinics.  Targeted exploration of the reasons 
behind low performance and collaboration on ways to improve performance in these clinics will 
benefit a larger number of patients than equal distribution among all clinics irrespective of 
performance. 
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Finally, the quarterly timeframe for routine monitoring used in this analysis is also 
conducive to performance improvement.  WHO recommends quarterly reporting of collaborative 
TB/HIV activities because that coincides with the reporting of outcomes of TB treatment by 
clinics to national programs.  We found quarterly measurements to be an appropriate interval in 
which to analyze our data by clinic.  It allowed significant number of patients to be enrolled in 
each clinic to provide stable trends in data. Because of low numbers of HIV positive patients in 
many of the clinics, uptake rates differed substantially in some clinics by month due to small 
sample sizes.  In these instances, more frequent analysis could lead to a misleading picture of 
clinic performance. Compiling uptake rates over three months provided adequate sample size in 
most cases to obtain a more realistic picture of collaborative activities.  Quarterly monitoring 
was also frequent enough to address performance concerns and is consistent with reporting of 
other TB clinic data to national tuberculosis programs.  If clinics or programs implement specific 
programs to improve performance, more frequent monitoring may be justified, but in routine 
clinic management quarterly assessment provides the needed guidance. 
 
 
Strengths and weaknesses 
Several strengths and limitations for this study exist.  One of the biggest strengths was 
that there were few missing data in this study.  Only 0.2, 1, and 3.3 percent of data for referral 
for HIV care and support, HIV status, and accepting HIV testing were missing, respectively.   
Observed results provide an accurate assessment of these three variables.  The rates of  three 
variables, post-test counseling, initiating CPT, and initiating or continuing ART, were recorded 
as occurring if a date of the activity was listed on the clinic TB treatment card.  All those without 
dates were considered not having received the counseling or commenced the prescription.  This 
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provides a conservative estimate of uptake activity rates as occasionally staff may have neglected 
to enter the date of a completed activity on a treatment card.  A second strength was that this was 
an effectiveness study, with collaborative activities being integrated as part of routine activities 
in established TB clinic settings without the hiring of additional staff.  Activities were 
implemented over a wide range of clinical presentations seen routinely in TB clinics.  
The true value of this effectiveness study in establishing HIV prevalence rates and 
measuring uptake activities may be limited by the difficulty of diagnosing TB in resource poor 
settings.  Study clinics used microscopy of sputum samples to diagnose smear positive TB, 
which has a low sensitivity.  Smear negative pulmonary TB cases and extra-pulmonary TB cases 
are diagnosed on clinical grounds by a physician, which has a low specificity.  With such 
uncertain diagnostic instruments, not all pulmonary TB patients are likely to be identified and 
subsequently tested for HIV, and a number of extra-pulmonary patients tested for HIV are likely 
to not have TB.  This could provide an underestimate or overestimate of the true TB/HIV co-
infection rate.   
Two other limitations involve the data collection and analysis.  First, despite a narrative 
field to record the reason for not initiating CPT existing on the TB treatment cards, this field was 
blank for the majority of patients.  If these data were provided it would assist clinics in 
identifying the hurdles to increasing CPT initiation rates.  Second, for this evaluation, data were 
extracted as individual observations into a central database by study staff.  This is a resource 
intensive process that is too complex for sustainable performance monitoring.  Because routine 
performance monitoring for clinics not in this study will occur using simpler WHO reporting 
forms, the degree of concordance between the two methods is unknown.  
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Finally, these clinics were selected for participation in the rollout of collaborative 
TB/HIV activities based on their location in the capital city, their enthusiasm, and preexisting 
infrastructure.  While most of the studied clinics succeeded in implementing collaborative 
activities,  such success may not be generalizable to all other clinic settings.  However, even if 
other settings may be more difficult, the experience gained by program staff in such settings may 
be useful in addressing the needs and limitations that other sites present as activities continue to 
be rolled out in other settings.     
 
Recommendations for TB clinics 
 This evaluation of uptake of collaborative TB/HIV activities has implications for TB 
clinics, both those in this study and others in similar and diverse environments, in regards to each 
of the recommended TB/HIV collaborative activities.  First, WHO recommended model for 
testing and counseling moved away from traditional, voluntary, opt-in, patient-initiated testing to 
a provider-initiated, opt-out approach. 
35, 38 
 Opt-out testing emphasizes the importance of HIV 
testing to patients and actively recruits patients for testing while still providing patient autonomy 
to consider the benefits and risks of testing in their particular situation.
39 
  In this study, provider-
initiated testing appeared well accepted and led to high HIV-testing rates.  In theory, the 
approach also required patients to provide informed consent allowing them to decline testing.  In 
this study, there was one clinic that reported 100 percent testing rates for several consecutive 
quarters.  In other words, out of several hundred patients, none refused testing.  While this is 
possible, it begs the question to what extent patients were provided with knowledge of testing 
and had informed consent obtained from them.  The testing routine at this clinic should be 
examined to ensure that patients are provided with the autonomy to decline testing.  Allowing 
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patients to opt-out of testing may require slightly more clinic time and resources to properly 
educate patients but is essential for protection of patient autonomy.  This perfect testing rate 
could also come from clinic staff reporting the completion of activities that did not occur.  The 
importance of truthfully recording figures should be routinely emphasized to all clinic staff in 
order to obtain the most accurate data possible.   
For those patients who do initially decline testing, TB treatment requires repeated 
encounters with medical services providing numerous opportunities for further education and 
examination of a patient’s reasons for refusal.  40   In the studied clinics, 98.8 percent of patients 
who accepted an HIV test did so at the initial offer of testing.  Such a high rates suggests that 
repeated offering of HIV testing may unnecessary and could instead lead to patients being 
coerced into testing against their will. 
Several authors have also discussed using TB clinics as a springboard for further HIV 
case finding.  Current WHO recommendations call for testing only TB positive patients.  Two 
studies have examined testing of all patients who present to TB clinics.  In one hospital in 
Uganda, a country without routine HIV-testing of HIV positive patients and limited access to 
ART, 39 percent of TB-positive patients were found to be HIV-positive while 49 percent of TB 
suspects not diagnosed with TB were HIV positive (p= 0.06).  Over 35 percent of the HIV-
positive patients identified would not have been diagnosed if only TB-positive patients received 
HIV testing.  
41 
  In a smaller cross-sectional study in Malawi, a country with expanding testing 
of HIV in TB clinics and increasing availability of ART, 56 percent of patients diagnosed with 
something other than TB in four TB clinics were found to be HIV-positive.
42 
  Both of these 
studies examined rates in areas of high HIV-prevalence and demonstrated that, as might be 
expected, patients who present with respiratory symptoms may be at higher risk of having HIV 
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than the general public.  In such settings, expanded provider-initiated, opt-out testing of all 
patients who present to HIV clinics may significantly increase case fining of HIV.  However, the 
benefit of testing all patients presenting to TB clinics in setting with a lower HIV prevalence is 
less clear. 
A second way to increase HIV case finding is by testing close contacts and family 
members of TB/HIV co-infected patients.  In a small, retrospective, cohort study done in the US, 
16 of 30 close contacts of TB/HIV co-infected patients (e.g. family members, houseguests, or 
friends) who had been tested for HIV were found to be HIV-positive.
43 
  In a cross-sectional 
study of TB/HIV infected patients in Thailand, 13.8 percent of contacts and 48.6 percent of 
spouses of TB/HIV co-infected patients were HIV-positive. 
44 
  In these studies, contacts of HIV 
negative patients were also found to be positive but at much lower rates.  These studies suggest 
that offering counseling and testing to close contacts of TB/HIV co-infected patients could 
identify substantial numbers of HIV-positive patients.  Testing such contacts may prove even 
more useful in higher prevalence settings like the DRC or other countries in Africa.  Even if TB 
clinics lack the resources to test all patients presenting to TB clinics or the contacts of TB/HIV 
co-infected patients, they could refer such populations to local VCT programs.  
Third, clinics should strive to identify HIV care and support resources in the community.  
Especially in areas with high rates of TB/HIV co-infection, testing TB patients will increase the 
number of patient needing HIV support services.  The most efficient way to provide services is  
through collaborative efforts with already established local resources.  If such resources do not 
exist within a community, TB clinics should explore promoting or developing such support 
services, with the help of VCT centers or other groups involved with HIV/AIDS care.  In the 
setting such as the one in this study, clinics with higher percentages of patient referred for HIV 
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care and support could provide assistance in identifying barriers to referral and guidance for the 
formation of support groups and activities.  By taking advantage of, strengthening, or building 
community support for co-infected patients, TB clinics help reduce the burden of suffering 
caused by TB/HIV and facilitate effective treatment. 
Anti-retroviral therapy has been shown to significantly reduce mortality among people 
living with HIV/AIDS.  While randomized trials of the effect of ART on the mortality of TB 
patients would be considered unethical, cohort studies demonstrated high rates of TB patients 
achieving undetectable viral loads and very few to no deaths while on therapy. 
17-22 
 According to 
the DRC’s 2005 UNAIDS progress report, just over 9,000 of the of the estimated 338,700 
eligible HIV-positive patients in the DRC have access to ART.  A total of 73 prescribing sites 
exist in 53 of the country’s 515 health districts.45   The few patients that received treatment 
during this study were fortunate enough to be treated by one of these few clinics, and most of 
those on ART were diagnosed with HIV and taking ART prior to TB clinic enrollment.  For 
effective uptake of ART to occur, the number of HIV prescribing clinics must be dramatically 
increased and the availability of anti-retroviral medications must be consistent.  Malawi has 
devised such a system that is thus far operating well.
46 
  Ideally, such clinics would be found in or 
alongside each TB clinic in urban and rural areas to maximize availability and minimize the 
burden placed on patients who need to regularly obtain services from both TB and HIV 
services.
47 
 
 TB reporting materials should be tailored to collecting information on collaborative 
TB/HIV activities.  In these study clinics, patient TB cards and clinic registers were altered to 
allow for centralized data gathering.  Other groups have proposed similar alterations.
48 
  In 
September 2006, WHO also published revised TB reporting forms and registers that guide clinics 
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in implementing collaborative activities.
49 
  One addition that does not appear on the new WHO 
treatment cards is a narrative field identifying the reason for not implementing CPT.  While 
contraindications to CPT are not common events, they occur frequent enough that a significant 
portion of the 18.5 percent of patients who did not initiate CPT in this study may have been 
ineligible.  Such information can help to address barriers to treatment and motivate clinic staff.  
With such revisions, reporting of such figures can be done by clinic staff and become normal 
parts of TB clinic duties.   
Finally, questions remain about the optimal way to rollout collaborative TB/HIV 
activities logistically and to ensure sustainability.  Two clinical questions concerning ART have 
been debated in the literature: the best treatment regimen and the correct time in relation to TB 
treatment for its implementation.
40 
  Other operational issues also exist, especially when 
considering implementation of ART.
48 
  While TB clinic staff were successfully trained in this 
study to provide HIV testing, post-test counseling, and CPT initiation, initiating ART requires 
determination of CD4 counts and management of an additional set of complex drug regimens.  If 
resources are available, integrating ART into TB clinics would be the most convenient for the 
patient as distance and cost of travel have been shown to significantly affect initiation of ART 
among TB patients.
50 
  However, few clinics are likely to have the resources for such programs 
and referral to HIV specific programs will likely be necessary.  Currently, patients are 
recommended to continue CPT and ART indefinitely beyond the completion of TB treatment, 
and TB clinics are unlikely to be able to support such patients indefinitely.  This again requires 
referral to additional facilities.  The best way to effectively organize responsibilities and optimize 
patient flow between facilities will need to be addressed in every location where collaborative 
activities are implemented.  Organizations must be adapted to local institutions, traditions, and 
 40 
resources, with an emphasis on reducing the effort required for patient to obtain treatment, and in 
all settings, medical staff must work to minimize risk of nosocomial transmission, especially of 
TB to susceptible HIV-positive patients. 
When considering expanding collaborative TB/HIV activities, program sustainability 
must be addressed from inception.  While the demand for such activities is high, implementing 
programs without planning for their long-term success has high potential for wasting resources.  
To the highest degree possible, the expertise of local leaders and professionals should be utilized 
and collaboration with existing programs should be explored and secured.  Local people should 
be hired and trained as program staff.  By obtaining local buy in and, if possible, local financing, 
programs are less likely to require outside support to be sustainable.    
 
Conclusion 
 Most collaborative TB/HIV activities were successfully implemented in 14 TB clinics in 
Kinshasa, DRC.  HIV testing, post-test counseling, and CPT initiation were acceptable in this 
setting with moderate rates of TB/HIV co-infection, while referral for HIV care and support and 
ART initiation were more sporadic.  Examining the uptake quarterly rates by individual clinics 
highlighted clinics with substandard performance in a timely way while maintaining adequate 
sample sizes.  In general, uptake was aided by including HIV testing and CPT initiation within 
TB clinics where staff was motivated to expand clinic scope.  Being a resource poor setting, 
availability of referral site for HIV care and support and ART were not readily available.  
Routine monitoring and evaluation can help to clarify the strengths and limitation of TB care on 
the clinic and system level in order to guide program implementation to address the large burden 
of suffering caused by TB/HIV co-infection. 
 41 
REFERENCES 
1. Global tuberculosis control: Surveillance, planning, financing. Geneva, World Health 
Organization: WHO; 2007;WHO/HTM/TB/2007.376. 
2. Corbett EL, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa: 
Opportunities, challenges, and change in the era of antiretroviral treatment. Lancet. 
2006;367:926-937. 
3. Nelson AM, Perriens JH, Kapita B, et al. A clinical and pathological comparison of the WHO 
and CDC case definitions for AIDS in Kinshasa, Zaire: Is passive surveillance valid? AIDS. 
1993;7:1241-1245. 
4. Scaling up antiretroviarl therapy in resource-limited settings: Treatment guidelines for a public 
health approach. 2003 revision. Geneva.: World Health Organization.; 2004. 
5. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole 
prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in 
Abidjan, Cote d'Ivoire: A randomised controlled trial. Lancet. 1999;353:1469-1475. 
6. Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D, Gilks CF. Effectiveness of 
cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS. 
2005;19:163-168. 
7. Mwaungulu FB, Floyd S, Crampin AC, et al. Cotrimoxazole prophylaxis reduces mortality in 
human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bull 
World Health Organ. 2004;82:354-363. 
8. Chimzizi R, Gausi F, Bwanali A, et al. Voluntary counselling, HIV testing and adjunctive 
cotrimoxazole are associated with improved TB treatment outcomes under routine conditions in 
Thyolo District, Malawi. Int J Tuberc Lung Dis. 2004;8:579-585. 
9. Zachariah R, Spielmann MP, Chinji C, et al. Voluntary counselling, HIV testing and 
adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS. 
2003;17:1053-1061. 
10. Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in 
the era of highly active antiretroviral therapy. J Infect Dis. 2004;190:1670-1676. 
11. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIV-infected persons in 
the era of highly active antiretroviral therapy. AIDS. 2002;16:75-83. 
12. Garcia de Olalla P, Martinez-Gonzalez MA, Cayla JA, et al. Influence of highly active anti-
retroviral therapy (HAART) on the natural history of extra-pulmonary tuberculosis in HIV 
patients. Int J Tuberc Lung Dis. 2002;6:1051-1057. 
 42 
13. Schiffer JT, Sterling TR. Timing of antiretroviral therapy initiation in tuberculosis patients 
with AIDS: A decision analysis. J Acquir Immune Defic Syndr. 2007;44:229-234. 
14. Anglaret X, Chêne G, Attia A, et al.  Early chemoprophylaxis with trimethoprim-
sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d’Ivoire: A randomised trial. 
Lancet. 1999; 353:1463-68. 
15. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active 
antiretroviral therapy: A collaborative analysis of prospective studies. Lancet. 2002;360:119-129. 
16. Bong CN, Chen SC, Jong YJ, et al. Outcomes of HIV-infected children with tuberculosis 
who are started on antiretroviral therapy in Malawi. Int J Tuberc Lung Dis. 2007;11:534-538. 
17. Jack C, Lalloo U, Karim QA, et al. A pilot study of once-daily antiretroviral therapy 
integrated with tuberculosis directly observed therapy in a resource-limited setting. J Acquir 
Immune Defic Syndr. 2004;36:929-934. 
18. Ribera E, Azuaje C, Lopez RM, et al. Once-daily regimen of saquinavir, ritonavir, 
didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD 
study). J Acquir Immune Defic Syndr. 2005;40:317-323. 
19. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Vibhagool A. Initiation of antiretroviral 
therapy in advanced AIDS with active tuberculosis: Clinical experiences from Thailand. J Infect. 
2006;52:188-194. 
20. Rolla VC, da Silva Vieira MA, Pereira Pinto D, et al. Safety, efficacy and pharmacokinetics 
of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV 
patients with tuberculosis. Clin Drug Investig. 2006;26:469-479. 
21. Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with 
rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for 
tuberculosis and HIV. J Antimicrob Chemother. 2006;58:1299-1302. 
22. Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, et al. Efavirenz trough levels are not 
associated with virological failure throughout therapy with 800 mg daily and a rifampicin-
containing antituberculosis regimen. J Antimicrob Chemother. 2006;58:1017-1023. 
23. Zachariah R, Teck R, Buhendwa L, et al. How can the community contribute in the fight 
against HIV/AIDS and tuberculosis? Aexample from a rural district in Malawi. Trans R Soc 
Trop Med Hyg. 2006;100:167-175. 
24. The voluntary HIV-1 counseling and testing efficacy study group.  Efficacy of voluntary 
HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: A 
randomised trial. Lancet. 2000;356:103-112. 
25. Weinhardt LS, Carey MP, Johnson BT, Bickham NL. Effects of HIV counseling and testing 
on sexual risk behavior: A meta-analytic review of published research, 1985-1997. Am J Public 
Health. 1999;89:1397-1405. 
 43 
26. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in 
persons aware and unaware they are infected with HIV in the United States: Implications for 
HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39:446-453. 
27. Glick P. Scaling up HIV voluntary counseling and testing in Africa: What can evaluation 
studies tell us about potential prevention impacts? Eval Rev. 2005;29:331-357. 
28. Global tuberculosis control : Surveillance, planning, financing : WHO report 2006. Geneva: 
World Health Organization; 2006;WHO/HTM/TB/2006.362. 
29. Sherman GG, Jones SA, Coovadia AH, Urban MF, Bolton KD. PMTCT programme--partial 
assessments can build the picture. S Afr Med J. 2004;94:934. 
30. World Health Organization. A guide to monitoring and evaluation for collaborative TB/HIV 
activities. Geneva: World Health Organization; 2004. 
31. Abouya L, Coulibaly IM, Wiktor SZ, et al. The Cote d'Ivoire national HIV counseling and 
testing program for tuberculosis patients: Implementation and analysis of epidemiologic data. 
AIDS. 1998;12:505-512. 
32. Zachariah R, Spielmann MP, Harries AD, Salaniponi FL. Voluntary counselling, HIV testing 
and sexual behaviour among patients with tuberculosis in a rural district of Malawi. Int J Tuberc 
Lung Dis. 2003;7:65-71. 
33. Chimzizi RB, Harries AD, Manda E, Khonyongwa A, Salaniponi FM. Counselling, HIV 
testing and adjunctive cotrimoxazole for TB patients in Malawi: From research to routine 
implementation. Int J Tuberc Lung Dis. 2004;8:938-944. 
34. Chimzizi R, Harries AD, Gausi F, et al. Scaling up HIV/AIDS and joint HIV-TB services in 
Malawi. Int J Tuberc Lung Dis. 2005;9:582-584. 
35. Stop TB Department and Department of HIV/AIDS. Intermin policy on collaborative 
TB/HIV activities. Geneva: WHO; 2004;WHO/HTM/TB/2004.330. 
36. BBC News. Timeline: Democratic republic of congo. Available at: 
http://news.bbc.co.uk/2/hi/africa/country_profiles/1072684.stm. Accessed 5/22, 2007. 
37. Langly GJ, Nolan KM, Norman CL, Provost LP. The Improvement Guide: A Practical 
Approach to Enhancing Organizational Performance. New York: Jossey-Bass; 1996. 
38. UNAIDS/World Health Organization. UNAIDS/WHO policy statement on HIV testing. 
Geneva: WHO; 2004. 
39. Jurgens R. Routinizing HIV testing in low- and middle-income countries: background paper. 
[Revised draft for comment.]. New York.: Open Society Institute.; 2006. Available from: 
http://www.soros.org/initiatives/health/articles_publications/publications/routinizing_20061213. 
Accessed 6 May 2007. 
 44 
40. Fujiwara PI, Clevenbergh P, Dlodlo RA. Management of adults living with HIV/AIDS in 
low-income, high-burden settings, with special reference to persons with tuberculosis. Int J 
Tuberc Lung Dis. 2005;9:946-958. 
41. Srikantiah P, Lin R, Walusimbi M, et al. Elevated HIV seroprevalence and risk behavior 
among Ugandan TB suspects: Implications for HIV testing and prevention. Int J Tuberc Lung 
Dis. 2007;11:168-174. 
42. Munthali L, Mwaungulu JN, Munthali K, Bowie C, Crampin AC. Using tuberculosis 
suspects to identify patients eligible for antiretroviral treatment. Int J Tuberc Lung Dis. 
2006;10:199-202. 
43. Reichler MR, Bur S, Reves R, et al. Results of testing for human immunodeficiency virus 
infection among recent contacts of infectious tuberculosis cases in the United States. Int J Tuberc 
Lung Dis. 2003;7:S471-8. 
44. Suggaravetsiri P, Yanai H, Chongsuvivatwong V, Naimpasan O, Akarasewi P. Integrated 
counseling and screening for tuberculosis and HIV among household contacts of tuberculosis 
patients in an endemic area of HIV infection: Chiang Rai, Thailand. Int J Tuberc Lung Dis. 
2003;7:S424-31. 
45. Programme National Multisectoriel de Lutte Contre le SIDA. Report on the implementation 
of the declaration of commitment of heads of state and of government for the response to 
HIV/AIDS in the DRC. Kinshasa, DRC.: UNGASS; 2005. Available from: 
http://www.unaids.org/en/Publications/2005ungassreporting/default.asp. Accessed 6 May 2007. 
46. Harries AD, Schouten EJ, Makombe SD, et al. Ensuring uninterrupted supplies of 
antiretroviral drugs in resource-poor settings: An example from Malawi. Bull World Health 
Organ. 2007;85:152-155. 
47. Harries AD, Hargreaves NJ, Chimzizi R, Salaniponi FM. Highly active antiretroviral therapy 
and tuberculosis control in Africa: Synergies and potential. Bull World Health Organ. 
2002;80:464-469. 
48. Harries AD, Boxshall M, Phiri S, et al. Providing HIV care for tuberculosis patients in sub-
Saharan Africa. Int J Tuberc Lung Dis. 2006;10:1306-1311. 
49. Expert Group on TB Recording and Reporting forms and registers, WHO Stop TB 
Department. Revised TB recording and reporting forms and registers – version 2006. World 
Health Organization; 2006. 
50. Zachariah R, Harries AD, Manzi M, et al. Acceptance of anti-retroviral therapy among 
patients infected with HIV and tuberculosis in rural Malawi is low and associated with cost of 
transport. PLoS ONE. 2006;1:e121. 
 
